Lupin Ltd

Lupin announced that the 44th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Lupin has allotted 2,358 equity shares under ESOP on 08 July 2026. With this allotment, the paid up equity share capital has increased to Rs 91,44,69,788 consisting of 45,72,34,894 equity shares of Rs 2/- each.

Lupin has fixed 17 July 2026 as record date for final dividend of Rs 18 per equity share for FY 2026.

Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6'C11 years, weighing at least 20 kg), adolescents (12'C17 years), and adults (''18 years) with non-dystrophic myotonic disorder.

The approval covers the 40 mg and 80 mg tablets as bioequivalent to Astellas' reference listed drug (RLD), Xtandi, for the approved indication. While Xtandi is currently marketed in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg tablets are expected to provide healthcare providers and patients with additional dosing flexibility. Enzalutamide is indicated for the treatment of certain types of prostate cancer. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. Powered by Capital Market - Live

The approval covers the 40 mg and 80 mg tablets as bioequivalent to Astellas' reference listed drug (RLD), Xtandi, for the approved indication. While Xtandi is currently marketed in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg tablets are expected to provide healthcare providers and patients with additional dosing flexibility. Enzalutamide is indicated for the treatment of certain types of prostate cancer. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. The counter fell 1.08% to settle at Rs 2,342.15 on Thursday, 25th June 2026. The NSE and BSE remain closed today on account of Muharram.Powered by Capital Market - Live

Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Enzalutamide Tablets, 40 mg, 80 mg, 120 mg, and 160 mg. The U.S. FDA has tentatively approved Lupin's Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi' Tablets of Astellas for the indication in the approved labeling. While Xtandi Tablets are traditionally available in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.

The product is bioequivalent to Edarbi of Azurity Pharmaceuticals and is indicated for the treatment of hypertension in adults to lower blood pressure. Lupin said it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market. According to IQVIA MAT April 2026 data, Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the United States. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.Powered by Capital Market - Live

The product is bioequivalent to Edarbi of Azurity Pharmaceuticals and is indicated for the treatment of hypertension in adults to lower blood pressure. Lupin said it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market. According to IQVIA MAT April 2026 data, Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the United States. Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. Shares of Lupin shed 0.91% to close at Rs 2,256.25 on the BSE.Powered by Capital Market - Live

Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec' (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain. This collaboration combines Lupin's global respiratory expertise and proven pMDI manufacturing excellence and ERN's robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.